UCB Stock Analysis: UCB | BR
Biotechnology | BR, Belgium | Market Cap: 40.478m EUR | 12M Return: 11.9% | BE0003739530 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 50.7M
Warnings
Tailwinds
Seasonality 11.6 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
UCB SA is a Belgium-based biopharmaceutical company founded in 1925 and headquartered in Brussels, listed on the Brussels exchange as a large-cap health care stock. The company focuses on developing and commercializing therapies for neurology and immunology diseases, with a global commercial footprint and an additional contract manufacturing business.
Its marketed portfolio spans multiple therapeutic areas. In neurology, UCB offers Vimpat, Keppra, and Briviact for epilepsy, Neupro for Parkinsons disease and restless legs syndrome, Nayzilam for seizure clusters, Fintepla for Dravet and Lennox-Gastaut syndromes, and RYSTIGGO and ZILBRYSQ for generalized myasthenia gravis. In immunology, Cimzia is approved for conditions including ankylosing spondylitis, Crohns disease, rheumatoid arthritis, and plaque psoriasis, while Bimzelx targets plaque psoriasis, psoriatic arthritis, hidradenitis suppurativa, and axial spondyloarthritis. The company also markets Evenity for postmenopausal osteoporosis and the consumer allergy brands Zyrtec and Xyzal.
The pipeline reflects continued investment in rare neurological and immune-mediated disorders, including KYGEVVI for thymidine kinase 2 deficiency, dapirolizumab pegol for systemic lupus erythematosus, STACCATO alprazolam for prolonged seizures, bepranemab for Alzheimers disease, and UCB9741 for atopic dermatitis, non-cystic fibrosis bronchiectasis, and COPD. As a research-driven biopharma, UCBs business model relies on patent-protected branded biologics and small molecules, late-stage pipeline progression, and lifecycle management across neurology and immunology franchises.
- Bimzelx sales surge offset Vimpat and Keppra generic erosion
- Evenity and RYSTIGGO launches diversify revenue beyond mature franchises
- Bepranemab Alzheimers readout creates major pipeline binary event
| Net Income: 2.19b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.07 > 0.02 and ΔFCF/TA -0.34 > 1.0 |
| NWC/Revenue: 10.83% < 20% (prev 20.30%; Δ -9.47% < -1%) |
| CFO/TA 0.09 > 3% & CFO 1.89b > Net Income 2.19b |
| Net Debt (3.00b) to EBITDA (3.29b): 0.91 < 3 |
| Current Ratio: 1.20 > 1.5 & < 3 |
| Outstanding Shares: last quarter (190.0m) vs 12m ago -2.57% < -2% |
| Gross Margin: 76.23% > 18% (prev 71.69%; Δ 4.55% > 0.5%) |
| Asset Turnover: 45.08% > 50% (prev 39.84%; Δ 5.23% > 0%) |
| Interest Coverage Ratio: 15.39 > 6 (EBIT TTM 2.66b / Interest Expense TTM 173.0m) |
| A: 0.04 (Total Current Assets 5.46b - Total Current Liabilities 4.54b) / Total Assets 20.6b |
| B: 0.45 (Retained Earnings 9.29b / Total Assets 20.6b) |
| C: 0.14 (EBIT TTM 2.66b / Avg Total Assets 18.9b) |
| D: 1.30 (Book Value of Equity 11.7b / Total Liabilities 8.98b) |
| Altman-Z'' = 4.07 = AA |
| DSRI: 1.12 (Receivables 2.58b/1.85b, Revenue 8.52b/6.85b) |
| GMI: 0.94 (GM 71.69% / 76.23%) |
| AQI: 1.08 (AQ_t 0.63 / AQ_t-1 0.59) |
| SGI: 1.24 (Revenue 8.52b / 6.85b) |
| TATA: 0.01 (NI 2.19b - CFO 1.89b) / TA 20.6b) |
| Beneish M = -2.75 (Cap -4..+1) = A |
As of August 22, 2026, the stock is trading at EUR 221.70 with a total of 253,935 shares traded. Over the past week, the price has changed by +4.43%, over one month by -9.10%, over three months by -7.97% and over the past year by +11.90%.
Current recommended Stop Loss: 212.60 (which is 4.1% or 1.3 ATR below the current price).
UCB has no consensus analysts rating.
P/E Trailing = 18.7379
P/E Forward = 19.8413
P/S = 4.7487
P/B = 3.6827
P/EG = 1.4262
Revenue TTM = 8.52b EUR
EBIT TTM = 2.66b EUR
EBITDA TTM = 3.29b EUR
Long Term Debt = 3.23b EUR (from longTermDebt, last quarter)
Short Term Debt = 217.0m EUR (from shortTermDebt, last quarter)
Debt = 3.80b EUR (from shortLongTermDebtTotal, last quarter) + Leases 209.0m
Net Debt = 3.00b EUR (calculated: Debt 3.80b - CCE 797.0m)
Enterprise Value = 43.5b EUR (40.5b + Debt 3.80b - CCE 797.0m)
Interest Coverage Ratio = 15.39 (Ebit TTM 2.66b / Interest Expense TTM 173.0m)
EV/FCF = 29.14x (Enterprise Value 43.5b / FCF TTM 1.49b)
FCF Yield = 3.43% (FCF TTM 1.49b / Enterprise Value 43.5b)
FCF Margin = 17.50% (FCF TTM 1.49b / Revenue TTM 8.52b)
Net Margin = 25.74% (Net Income TTM 2.19b / Revenue TTM 8.52b)
Gross Margin = 76.23% ((Revenue TTM 8.52b - Cost of Revenue TTM 2.03b) / Revenue TTM)
Gross Margin QoQ = 77.56% (prev 74.89%)
Tobins Q-Ratio = 2.11 (Enterprise Value 43.5b / Total Assets 20.6b)
Interest Expense / Debt = 4.56% (Interest Expense 173.0m / Debt 3.80b)
Taxrate = 13.42% (340.0m / 2.53b)
NOPAT = 2.30b (EBIT 2.66b * (1 - 13.42%))
Current Ratio = 1.20 (Total Current Assets 5.46b / Total Current Liabilities 4.54b)
Debt / Equity = 0.33 (Debt 3.80b / totalStockholderEquity, last quarter 11.7b)
Debt / EBITDA = 0.91 (Net Debt 3.00b / EBITDA 3.29b)
Debt / FCF = 2.01 (Net Debt 3.00b / FCF TTM 1.49b)
Total Stockholder Equity = 10.6b (last 4 quarters mean from totalStockholderEquity)
RoA = 11.60% (Net Income 2.19b / Total Assets 20.6b)
RoE = 20.78% (Net Income TTM 2.19b / Total Stockholder Equity 10.6b)
RoCE = 19.31% (EBIT 2.66b / Capital Employed (Equity 10.6b + L.T.Debt 3.23b))
RoIC = 14.51% (NOPAT 2.30b / Invested Capital 15.9b)
WACC = 6.32% (E(40.5b)/V(44.3b) * Re(6.54%) + D(3.80b)/V(44.3b) * Rd(4.56%) * (1-Tc(0.13)))
Discount Rate = 6.54% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -42.81 | Cagr: -0.90%
[DCF] Terminal Value 77.92% ; FCFF base≈1.42b ; Y1≈1.62b ; Y5≈2.37b
[DCF] Fair Price = 171.1 (EV 35.6b - Net Debt 3.00b = Equity 32.6b / Shares 190.7m; r=8.35% [WACC [floored]]; 5y FCF grow 14.68% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: N/A | # QB: 0
Revenue Correlation: 99.32 | Revenue CAGR: 22.69% | SUE: N/A | # QB: 0
EPS current Year (2026-12-31): EPS=11.62 | Chg30d=+7.56% | Revisions=+22% | GrowthEPS=+16.3% | GrowthRev=+12.0%
EPS next Year (2027-12-31): EPS=13.93 | Chg30d=+2.73% | Revisions=+0% | GrowthEPS=+19.9% | GrowthRev=+11.7%
[Analyst] Revisions Ratio: +13% (up=7, down=5)